Bevacizumab

Evidence Level: L5

Predicted Indications: 10

Bevacizumab

Pharmacist Assessment Report

Bevacizumab: anti-VEGF-A monoclonal antibody → epiglottis neoplasm

One-Sentence Summary

Bevacizumab is a monoclonal antibody that neutralises VEGF-A and is listed in Australia as a marketed product. The TxGNN model predicts it may be useful for epiglottis neoplasm, but no clinical trials or publications were found for this disease, so the prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Epiglottis neoplasm
TxGNN Prediction Score	0.9990
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on what is generally known, bevacizumab binds and neutralises VEGF-A, which can limit the growth of new blood vessels that tumours depend on.

Because many head and neck tumours rely on angiogenesis, there is a plausible biological reason to consider an anti-VEGF agent for a tumour of the epiglottis. This link is theoretical only. No trials or publications were retrieved for epiglottis neoplasm, so the prediction cannot be considered supported by clinical data.

Clinical Trial Evidence

Currently no related clinical trials registered for this disease.

Literature Evidence

Currently no related literature available for this disease.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 12479T	Mvasi	Solution for I.V. infusion 100 mg in 4 mL	Not recorded in the local data

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-VEGF monoclonal antibody)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the Product Information (PI) warnings and precautions
Handling Protection	Please refer to the Product Information (PI) warnings and precautions

Safety Considerations

Label warnings and contraindications are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.

Drug Interactions: 22 interactions were recorded in the data compiled for this report. Major-level interactions include:

Deferiprone
Samarium (153Sm) lexidronam
Panitumumab
Sunitinib
Thalidomide

Moderate-level interactions include bisphosphonates (alendronic, risedronic, etidronic, pamidronic and tiludronic acids, ibandronate), colony-stimulating factors (filgrastim, pegfilgrastim, sargramostim), palifermin, idelalisib, strontium chloride Sr-89, radium Ra 223 dichloride, romosozumab and sodium phosphate (P32).

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for epiglottis neoplasm has no supporting trials or publications, so the evidence level is L5 (model prediction only). The mechanistic argument is generic and does not justify moving forward on its own.

To proceed, the following is needed:

A targeted literature and trial search for bevacizumab in laryngeal, supraglottic and wider head and neck tumours
Mechanism of action data
Label warnings and contraindications from the TGA Product Information
Clarification of the approved indication for the Australian product
Assessment of the risk-benefit balance in this rare tumour site
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.